Saturday 7 November 2026 Export ACRS’s income statement to Excel — free account

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.

Revenue: −55.1%
EPS: 0.00%
Free cash flow: −119.9%

Quarter to September 2026, against a year earlier

3.88 0.27 +7.48%

Follow ACRS

Alert me

Market cap: $559.5M
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 3/9
Altman Z: −5.60
Beneish M: −2.97
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 1.36

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	—	—	—	—	—	—

Insider Ownership 25.69%

Capital & Financial Ratios $m

Size

Market Cap 559.49

Revenue ttm 6.40

Net income ttm (79.63)

Free cash flow ttm (75.31)

Net debt Q (114.29)

Valuation

P/E 0.00

Forward P/E (6.16)

Price / sales 90.59

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.48

Financial health

Current ratio Q 5.09

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q −55.11%

Operating income growth Q −24.46%

EPS, this year −16.04%

EPS, next year A −12.85%

Revenue, next year A −21.03%

EPS, past 5 yrs —

EPS, next 5 yrs A −12.16%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.95%

10-year low 10-year high

P/B against its own 10 years 57.51%

10-year low 10-year high

EV/Sales against its own 10 years 71.59%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	119	114	91	114
Receivables	0	12	6	—
Inventory	—	—	—	—
Other	—	—	—	—
	129	126	96	123

	2023	2024	2025	Q'26
Payables	9	5	13	9
ST’ Debt	—	—	—	—
Other	3	3	3	—
	31	32	29	24

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.84%	(35.93%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.09%	22.32%	(19.50%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.16 Actual −0.15

−0.17 −0.15 −0.14 −0.13 −0.11

Q3 FY25 Beat +0.01

Q4 FY25 Miss −0.01

Q1 FY26 Beat +0.01

Q2 FY26 Beat +0.01

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.13	−0.12	Beat by 0.01
Q4 FY25	−0.15	−0.16	Miss by 0.01
Q1 FY26	−0.16	−0.15	Beat by 0.01
Q2 FY26	−0.16	−0.15	Beat by 0.01
Q3 FY26	−0.16	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.15)	(0.15)	(0.12)	—	—
’25	(0.12)	(0.13)	(0.12)	(0.16)	(0.53)
’24	(0.24)	(0.15)	(0.11)	(1.01)	(1.71)
’23	(0.42)	(0.42)	(0.41)	(0.02)	(1.27)
’22	(0.31)	(0.31)	(0.30)	(0.41)	(1.33)
’21	(0.57)	(0.34)	(0.35)	(0.37)	(1.60)
’20	(0.37)	(0.28)	(0.25)	(0.30)	(1.20)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	2	1	—	—
’25	1	2	3	1	8
’24	2	3	4	9	19
’23	3	2	9	18	31
’22	1	2	19	8	30
’21	2	2	2	2	7
’20	1	2	1	2	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(20)	(24)	—	—
’25	(13)	(10)	(11)	(13)	(47)
’24	(21)	(12)	22	(9)	(20)
’23	(26)	(21)	(25)	(7)	(78)
’22	(21)	(20)	(8)	(19)	(68)
’21	(12)	(12)	(11)	(17)	(52)
’20	(7)	(11)	(12)	(9)	(39)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(20)	(24)	—	—
’25	(13)	(10)	(11)	(13)	(47)
’24	(21)	(12)	22	(9)	(56)
’23	(27)	(21)	(25)	(7)	(80)
’22	(21)	(20)	(8)	(19)	(68)
’21	(12)	(12)	(11)	(17)	(52)
’20	(7)	(11)	(12)	(9)	(39)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	2	6	4	6	7	30	31	19	8	6		+21.2%	6	5	6	(9.8%)
	Gross margin, %	0.00	28.28	29.62	4.07	20.81	30.29	59.80	42.14	17.43	6.93	0.00		+6.9 pt	Powerpack Aclaris Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to shrink 9.8% a year to 2028 — slower than the 21.2% of the last 8 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(48)	(70)	(82)	(114)	(51)	(91)	(87)	(89)	(132)	(65)	(80)		+3.4%
	EBT margin, %	0.00	(4,180.21)	(1,334.81)	(2,686.11)	(791.98)	(1,343.96)	(292.11)	(284.32)	(705.48)	(829.58)	(1,244.09)		(829.6) pt
	Net income	(48)	(69)	(133)	(161)	(51)	(91)	(87)	(88)	(132)	(65)	(80)		+3.4%
Per share, $
Per share, $	Revenue	0.00	0.06	0.19	0.10	0.15	0.12	0.46	0.45	0.24	0.06	0.04		n/m
	Earnings	(2.25)	(2.44)	(4.03)	(3.90)	(1.20)	(1.60)	(1.33)	(1.27)	(1.71)	(0.53)	(0.58)		(14.8%)
	Cash flow	(1.62)	(1.95)	(3.06)	(2.33)	(0.91)	(0.92)	(1.04)	(1.12)	(0.26)	(0.38)	(0.50)		(14.7%)
	Capex	(0.01)	(0.04)	(0.04)	(0.04)	(0.01)	(0.01)	(0.01)	(0.02)	(0.46)	0.00	0.00		(24.1%)
	Free cash flow	(1.63)	(1.99)	(3.10)	(2.37)	(0.92)	(0.92)	(1.05)	(1.14)	(0.72)	(0.39)	(0.50)		(14.8%)
	Book value	7.91	8.02	6.54	1.69	0.89	3.48	3.03	2.25	2.01	0.84	1.12		(22.0%)
	Shares, m	21	28	33	41	43	57	65	70	77	123	136		+21.4%
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	0.00	37.28	18.51	42.46	122.00	33.03	2.35	10.24	47.14	90.59		34.8
	P/B	—	3.12	1.33	1.12	7.31	4.18	4.97	0.47	1.23	3.58	3.48		3.0
	EV/Sales	—	0.00	19.31	1.61	35.75	95.28	26.08	(1.12)	4.75	36.92	74.41		24.3
	EV/FCF	—	(9.12)	(1.45)	(0.07)	(5.93)	(12.28)	(11.38)	0.44	(4.40)	(6.12)	(6.32)		(5.6)
Cash, $m
Cash, $m	Operating cash flow	(35)	(55)	(101)	(96)	(39)	(52)	(68)	(78)	(20)	(47)	(75)		+3.5%
	Capex	0	(1)	(1)	(2)	0	0	(1)	(1)	(36)	0	0		(7.9%)
	Free cash flow	(35)	(56)	(102)	(98)	(39)	(52)	(68)	(80)	(56)	(47)	(75)		+3.4%
Balance, $m
Balance, $m	Working capital	132	187	152	61	43	182	210	98	94	68	99		(7.2%)
	Net debt	(137)	(194)	(138)	(71)	(43)	(191)	(218)	(119)	(114)	(91)	(114)		(4.5%)
	Shareholders’ equity	169	225	215	70	38	197	198	157	156	103	167		(5.4%)
Returns, %
Returns, %	ROA	(35.59)	(32.66)	(51.14)	(86.32)	(60.34)	(56.44)	(34.36)	(39.15)	(63.23)	(34.10)	(40.66)		+1.5 pt
	ROIC	(94.07)	(108.19)	(68.76)	0.00	0.00	(946.13)	0.00	(159.82)	(211.41)	(387.11)	(107.72)		(293.0) pt
	ROE	(36.70)	(34.72)	(60.28)	(113.22)	(94.86)	(77.34)	(44.01)	(49.88)	(84.46)	(50.20)	(55.51)		(13.5) pt
People
People	Employees	31	96	169	77	60	77	105	91	64	73	—		+10.0%
	Revenue/emp, $m	0.00	0.02	0.04	0.05	0.11	0.09	0.28	0.34	0.29	0.11	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OBX Obsidian Therapeutics, Inc	$593.0M	—	—	—	n/m	—	—	0.00%	Compare
OLMA Olema Pharmaceuticals, Inc.	$591.5M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
APMD Apnimed, Inc.	$589.5M	0.8×	4.6×	—	—	—	89.98%	(96.89%)	Compare
NVCT Nuvectis Pharma, Inc.	$579.8M	— (loss-making)	—	—	n/m	−34.57% (below 0%: shrinking)	—	0.00%	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$568.5M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
ACRS Aclaris Therapeutics, Inc.	$559.5M	— (loss-making)	— (loss-making)	−55.11% (below 0%: shrinking)	n/m	−119.93% (below 0%: shrinking)	0.00%	(1,441.19%)
IAM Iambic Therapeutics, Inc.	$551.7M	—	—	—	—	—	—	—	Compare
BCAX Bicara Therapeutics Inc.	$542.0M	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
VALN Valneva SE Sponsored ADR	$536.5M	59.3×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
Median of peers	$574.1M	—	—	—	—	−54.33%	15.29%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 23 April 2026

Ownership

Directors and executive officers, together 4.80%

BML Investment Partners, L.P. 10.20%

Biosion, Inc. 8.10%

Deep Track Capital, LP 6.70%

Entities associated with Vivo Capital LLC 6.40%

RA Capital Management, L.P. 5.50%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Aclaris Therapeutics, Inc. (ACRS) Latest News

5 Nov

Impact 3 · 6:59 AM · GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update

27 Oct

Impact 4 · 6:04 PM · MarketBeat

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Impact 4 · 10:38 AM · MT Newswires

Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering

Impact 4 · 8:40 AM · Stocktwits

Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?

Impact 4 · 6:00 AM · GlobeNewswire

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Impact 3 · 6:43 AM · GlobeNewswire

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

21 Oct

Impact 3 · 8:40 AM · Zacks

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

6 Aug

Impact 4 · 4:35 PM

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Impact 4 · 4:35 PM

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Impact 3 · 6:59 AM

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

4 Jun

Impact 3 · 3:02 PM · MarketBeat

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052

7 May

Impact 3 · 8:50 AM · Zacks

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Impact 3 · 6:59 AM · GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

28 Apr

Impact 4 · 10:17 AM · MarketBeat

Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus

Impact 4 · 6:30 AM · GlobeNewswire

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

27 Apr

Impact 3 · 4:45 PM · GlobeNewswire

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

14 Apr

Impact 4 · 6:04 PM · MarketBeat

Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming

27 Mar

Impact 4 · 10:10 AM · GlobeNewswire

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

20 Mar

Impact 3 · 11:00 AM · GlobeNewswire

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

18 Mar

Impact 4 · 6:55 AM · GlobeNewswire

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

10 Mar

Impact 4 · 2:51 PM · MarketBeat

Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference

26 Feb

Impact 4 · 6:58 AM · GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Impact 3 · 10:59 AM · MarketBeat

Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference

Impact 3 · 9:45 AM

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Impact 3 · 7:09 AM · Associated Press Finance

Aclaris: Q4 Earnings Snapshot

24 Feb

Impact 4 · 7:00 AM

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

12 Feb

Impact 4 · 7:27 PM · MarketBeat

Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026

10 Feb

Impact 4 · 1:05 PM · Simply Wall St.

February 2026's Promising Penny Stocks To Consider

27 Jan

Impact 4 · 6:55 AM · GlobeNewswire

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

13 Jan

Impact 4 · 7:44 AM · TipRanks

Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052

Aclaris Therapeutics, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Aclaris Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 23 April 2026

Ownership

Aclaris Therapeutics, Inc. (ACRS) Latest News

5 Nov

27 Oct

21 Oct

6 Aug

4 Jun

7 May

28 Apr

27 Apr

14 Apr

27 Mar

20 Mar

18 Mar

10 Mar

26 Feb

24 Feb

12 Feb

10 Feb

27 Jan

13 Jan

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Aclaris Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 23 April 2026

Ownership

Aclaris Therapeutics, Inc. (ACRS) Latest News

5 Nov

27 Oct

21 Oct

6 Aug

4 Jun

7 May

28 Apr

27 Apr

14 Apr

27 Mar

20 Mar

18 Mar

10 Mar

26 Feb

24 Feb

12 Feb

10 Feb

27 Jan

13 Jan

Stockrow Weekly